BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29683659)

  • 1. The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).
    Pike KG; Barlaam B; Cadogan E; Campbell A; Chen Y; Colclough N; Davies NL; de-Almeida C; Degorce SL; Didelot M; Dishington A; Ducray R; Durant ST; Hassall LA; Holmes J; Hughes GD; MacFaul PA; Mulholland KR; McGuire TM; Ouvry G; Pass M; Robb G; Stratton N; Wang Z; Wilson J; Zhai B; Zhao K; Al-Huniti N
    J Med Chem; 2018 May; 61(9):3823-3841. PubMed ID: 29683659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
    Degorce SL; Barlaam B; Cadogan E; Dishington A; Ducray R; Glossop SC; Hassall LA; Lach F; Lau A; McGuire TM; Nowak T; Ouvry G; Pike KG; Thomason AG
    J Med Chem; 2016 Jul; 59(13):6281-92. PubMed ID: 27259031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
    Jones GN; Rooney C; Griffin N; Roudier M; Young LA; Garcia-Trinidad A; Hughes GD; Whiteaker JR; Wilson Z; Odedra R; Zhao L; Ivey RG; Howat WJ; Harrington EA; Barrett JC; Ramos-Montoya A; Lau A; Paulovich AG; Cadogan EB; Pierce AJ
    Br J Cancer; 2018 Nov; 119(10):1233-1243. PubMed ID: 30385821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors.
    Han SY; Choi JW; Yang J; Chae CH; Lee J; Jung H; Lee K; Ha JD; Kim HR; Cho SY
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2837-42. PubMed ID: 22450128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
    Riches LC; Trinidad AG; Hughes G; Jones GN; Hughes AM; Thomason AG; Gavine P; Cui A; Ling S; Stott J; Clark R; Peel S; Gill P; Goodwin LM; Smith A; Pike KG; Barlaam B; Pass M; O'Connor MJ; Smith G; Cadogan EB
    Mol Cancer Ther; 2020 Jan; 19(1):13-25. PubMed ID: 31534013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.
    Lücking U; Wortmann L; Wengner AM; Lefranc J; Lienau P; Briem H; Siemeister G; Bömer U; Denner K; Schäfer M; Koppitz M; Eis K; Bartels F; Bader B; Bone W; Moosmayer D; Holton SJ; Eberspächer U; Grudzinska-Goebel J; Schatz C; Deeg G; Mumberg D; von Nussbaum F
    J Med Chem; 2020 Jul; 63(13):7293-7325. PubMed ID: 32502336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390.
    Pike KG; Hunt TA; Barlaam B; Benstead D; Cadogan E; Chen K; Cook CR; Colclough N; Deng C; Durant ST; Eatherton A; Goldberg K; Johnström P; Liu L; Liu Z; Nissink JWM; Pang C; Pass M; Robb GR; Roberts C; Schou M; Steward O; Sykes A; Yan Y; Zhai B; Zheng L
    J Med Chem; 2024 Feb; 67(4):3090-3111. PubMed ID: 38306388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.
    Knegtel R; Charrier JD; Durrant S; Davis C; O'Donnell M; Storck P; MacCormick S; Kay D; Pinder J; Virani A; Twin H; Griffiths M; Reaper P; Littlewood P; Young S; Golec J; Pollard J
    J Med Chem; 2019 Jun; 62(11):5547-5561. PubMed ID: 31074988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis of human ATM kinase inhibition.
    Stakyte K; Rotheneder M; Lammens K; Bartho JD; Grädler U; Fuchß T; Pehl U; Alt A; van de Logt E; Hopfner KP
    Nat Struct Mol Biol; 2021 Oct; 28(10):789-798. PubMed ID: 34556870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATM in DNA repair in cancer.
    Jin MH; Oh DY
    Pharmacol Ther; 2019 Nov; 203():107391. PubMed ID: 31299316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156.
    Koneru B; Farooqi A; Nguyen TH; Chen WH; Hindle A; Eslinger C; Makena MR; Burrow TA; Wilson J; Smith A; Pilla Reddy V; Cadogan E; Durant ST; Reynolds CP
    Sci Transl Med; 2021 Aug; 13(607):. PubMed ID: 34408079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.
    Barlaam B; Cadogan E; Campbell A; Colclough N; Dishington A; Durant S; Goldberg K; Hassall LA; Hughes GD; MacFaul PA; McGuire TM; Pass M; Patel A; Pearson S; Petersen J; Pike KG; Robb G; Stratton N; Xin G; Zhai B
    ACS Med Chem Lett; 2018 Aug; 9(8):809-814. PubMed ID: 30128072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of ataxia telangiectasia mutated kinase inhibitors.
    Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Moravcova S; Hanzlikova H; Kuca K
    Mini Rev Med Chem; 2014; 14(10):805-11. PubMed ID: 25138084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
    Min J; Guo K; Suryadevara PK; Zhu F; Holbrook G; Chen Y; Feau C; Young BM; Lemoff A; Connelly MC; Kastan MB; Guy RK
    J Med Chem; 2016 Jan; 59(2):559-77. PubMed ID: 26632965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a cell-based, high-throughput screening assay for ATM kinase inhibitors.
    Guo K; Shelat AA; Guy RK; Kastan MB
    J Biomol Screen; 2014 Apr; 19(4):538-46. PubMed ID: 24464432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation of
    Li H; Yang W; Zhang M; He T; Zhou F; G Herman J; Hu L; Guo M
    Epigenomics; 2021 Sep; 13(17):1403-1419. PubMed ID: 34558311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kδ selective inhibitors.
    Bahekar R; Dave B; Soman S; Patel D; Chopade R; Funde R; Kumar J; Sachchidanand S; Giri P; Chatterjee A; Mahapatra J; Vyas P; Ghoshdastidar K; Bandyopadhyay D; Desai RC
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1313-1319. PubMed ID: 30975623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.
    Eltze T; Boer R; Wagner T; Weinbrenner S; McDonald MC; Thiemermann C; Bürkle A; Klein T
    Mol Pharmacol; 2008 Dec; 74(6):1587-98. PubMed ID: 18809672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
    Hollick JJ; Rigoreau LJ; Cano-Soumillac C; Cockcroft X; Curtin NJ; Frigerio M; Golding BT; Guiard S; Hardcastle IR; Hickson I; Hummersone MG; Menear KA; Martin NM; Matthews I; Newell DR; Ord R; Richardson CJ; Smith GC; Griffin RJ
    J Med Chem; 2007 Apr; 50(8):1958-72. PubMed ID: 17371003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure and activity relationships leading to the discovery of ICI D2138, a selective, potent and orally active inhibitor of 5-lipoxygenase.
    Crawley GC; Bird TG; Bruneau P; Dowell RI; Edwards PN; Foster SJ; Girodeau JM; McMillan RM; Walker ER; Waterson D
    J Lipid Mediat; 1993; 6(1-3):249-57. PubMed ID: 8395247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.